Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

Therapeutic Advances in Musculoskeletal Disease

Volumn 2, Issue 5, 2010, Pages 271-278

  Schett, Georg ^a   Sloan, Victor S ^b   Stevens, Randall M ^b   Schafer, Peter ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CELGENE CORPORATION   (United States)

Author keywords

apremilast; cyclic adenosine monophosphate; phosphodiesterase 4; psoriasis; psoriatic arthritis

Indexed keywords

EID: 84993740524     PISSN: 1759720X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1759720X10381432     Document Type: Review

References (36)

1. Abrahamsen, H., Baillie, G., Ngai, J., Vang, T., Nika, K., Ruppelt, A. et al. (2004) TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173: 4847-4858.
2. Alves, A.C., Pires, A.L., Cruz, H.N., Serra, M.F., Diaz, B.L., Cordeiro, R.S. et al. (1996) Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur J Pharmacol 312: 89-96.
3. Bjørgo, E. and Taskén, K. (2010) Novel mechanism of signaling by CD28. Immunol Lett 129: 1-6.
4. Bolger, G.B., Peden, A.H., Steele, M.R., MacKenzie, C., McEwan, D.G., Wallace, D.A. et al. (2003) Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 278: 33351-33363.
5. Borska, L., Fiala, Z., Krejsek, J., Andrys, C., Vokurkova, D., Hamakova, K. et al. (2007) Immunologic changes in TNF-α, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol 24: 607-612.
6. Bos, J.D., de Rie, M.A., Teunissen, M.B. and Piskin, G. ( 2005) Psoriasis: dysregulation of innate immunity. Br J Dermatol 152: 1098-1107.
7. Conti, M. and Beavo, J. ( 2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
8. Eigler, A., Siegmund, B., Emmerich, U., Baumann, K.H., Hartmann, G. and Endres, S. ( 1998) Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 63: 101-107.
9. Essayan, D.M., Huang, S.K., Kagey-Sobotka, A. and Lichtenstein, L.M. ( 1997) Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 99: 28-37.
10. Essayan, D.M., Huang, S.K., Undem, B.J., Kagey-Sobotka, A. and Lichtenstein, L.M. ( 1994) Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 153: 3408-3416.
11. Giembycz, M.A. ( 2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001 10: 1361-1379.
12. Gobejishvili, L., Barve, S., Joshi-Barve, S. and McClain, C. ( 2008) Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 295: G718-G724.
13. Gordon, J.N., Prothero, J.D., Thornton, C.A., Pickard, K.M., Di Sabatino, A., Goggin, P.M. et al. (2009) CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-alpha and MMP-3 production in patients with inflammatory bowel disease. J Crohn's Colitis 3: 175-182.
14. Gottlieb, A.B., Strober, B., Krueger, J.G., Rohane, P., Zeldis, J.B., Hu, C.C. et al. (2008) An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 24: 1529-1538.
15. Houslay, M.D. and Adams, D.R. ( 2003) PDE 4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18.
16. Houslay, M.D., Baillie, G.S. and Maurice, D.H. ( 2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100: 950-966.
17. Houslay, M.D., Schafer, P. and Zhang, K.Y. ( 2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10: 1503-1519.
18. Jimenez, J.L., Punzon, C., Navarro, J., Munoz-Fernandez, M.A. and Fresno, M. ( 2001) Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-κB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299: 753-759.
19. Jones, N.A., Boswell-Smith, V., Lever, R. and Page, C.P. ( 2005) The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18: 93-101.
20. Kwak, H.J., Song, J.S., Heo, J.Y., Yang, S.D., Nam, J.-Y. and Cheon, H.G. ( 2005) Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p 38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharm Exp Ther 315: 1188-1195.
21. Liu, J., Chen, M. and Wang, X. ( 2000) Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 101: 61-67.
22. Man, H.W., Schafer, P., Wong, L.M., Patterson, R.T., Corral, L.G., Raymon, H. et al. (2009) Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methane-sulfonylethyl]-1,3-dioxo-2,3-dihy dro-1 H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 52: 1522-1524.
23. McCann, F.E., Palfreeman, A.C., Andrews, M., Perocheau, D.P., Inglis, J.J., Schafer, P. et al. (2010) Apremilast, a novel PDE 4 inhibitor, inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 12: R107.
24. Ollivier, V., Parry, G.C.N., Cobb, R.R., de Prost, D. and Mackman, N. (1996) Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271: 20828-20835.
25. Papp, K., Zeldis, J.B., Rohane, P. and Thaci, D. ( 2008) A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-1004 in subjects with moderate to severe psoriasis [abstract P2614]. J Am Acad Dermatol 58: AB3.
26. Platzer, C., Fritsch, E., Elsner, T., Lehmann, M.H., Volk, H.D. and Prosch, S. ( 1999) Cyclic adenosine monophosphate-responsive elements are involved in the transcriptional activation of the human IL-10 gene in monocytic cells. Eur J Immunol 29: 3098-3104.
27. Richter, W. and Conti, M. ( 2004) The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem 279: 30338-30348.
28. Robichaud, A., Stamatiou, P.B., Jin, S.L., Lachance, N., MacDonald, D., Laliberté, F. et al. (2002) Deletion of phosphodiesterase 4D in mice shortens alpha (2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110: 1045-1052.
29. Schafer, P.H. ( 2005) Maximizing efficacy of phosphodiesterase 4 inhibitors for COPD and asthma: therapeutic index of CC-10004. SMi Asthma and COPD Conference, SMi Group Ltd: London, UK, 28 April 2005.
30. Schafer, P., Parton, A., Gandhi, A., Capone, L., Adams, M., Wu, L. et al. (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159: 842-855.
31. Schett, G., Wollenhaupt, J., Papp, K., Joos, R., de Vlam, K.L., Rodrigues, J. et al. (2009) Apremilast is active in the treatment of psoriatic arthritis (PsA). Arthritis Rheum 60(Suppl. 10): 1258.
32. Seldon, P.M., Barnes, P.J., Meja, K. and Giembycz, M.A. ( 1995) Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 48: 747-757.
33. Seldon, P.M., Barnes, P.J. and Giembycz, M.A. ( 1998) Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes. Cell Biochem Biophys 29: 179-201.
34. Shepherd, M.C., Baillie, G.S., Stirling, D.I. and Houslay, M.D. ( 2004) Remodelling of the PDE 4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U 937 cells. Br J Pharmacol 142: 339-351.
35. Tasken, K. and Aandahl, E.M. ( 2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84: 137-167.
36. Yarwood, S.J., Steele, M.R., Scotland, G., Houslay, M.D. and Bolger, G.B. ( 1999) The RACK 1 signaling scaffold protein selectively interacts with the cAMPspecific phosphodiesterase PDE4D5 isoform. J Biol Chem 274: 14909-14917.